Immunorho (Human Anti-D Immunoglobulin)

The immunoglobulin binds to any Rh(D) positive red blood cells that may enter the maternal circulation, masking the D antigen and preventing the mother’s immune system from recognizing and producing anti‑D antibodies, thereby providing passive protection.

The dose of Immunorho is determined by the prescribing clinician based on the patient’s Rh status, gestational age and clinical guidelines. Specific dosing regimens are not disclosed here.

Immunorho is administered to pregnant women to protect the fetus; it is considered safe when the clinical benefit outweighs any potential risk. Limited data are available for breastfeeding, so a risk‑benefit assessment should be performed by the healthcare provider.

To place an order, submit an enquiry on the Immunorho product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Immunorho contains purified Human Anti‑D Immunoglobulin and offers comparable efficacy to other licensed Rh immune globulins. Differences may lie in manufacturing processes, concentration, and storage requirements, but clinical outcomes for preventing Rh sensitization are generally similar across products.

Immunorho must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Immunorho is given by intramuscular injection, typically into the deltoid or gluteal muscle, by a qualified healthcare professional following aseptic technique.

Serious risks include severe allergic reactions such as anaphylaxis, acute hemolysis, renal impairment, serum‑sickness‑like reactions, and profound hypotension. Immediate medical attention is required if any of these occur.

Patients with a known hypersensitivity to human immunoglobulins, those with IgA deficiency who have experienced prior severe reactions, or individuals for whom the benefit does not outweigh the risk should not receive Immunorho. Clinical judgment is essential.